<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825551</url>
  </required_header>
  <id_info>
    <org_study_id>91-01-54-17265</org_study_id>
    <nct_id>NCT01825551</nct_id>
  </id_info>
  <brief_title>The Effect of GCSF in the Treatment of ALS Patients</brief_title>
  <official_title>The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor
      (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient`s function</measure>
    <time_frame>one year</time_frame>
    <description>based on revised ALS Functional Rating scale (ALSFRS-r)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mobilizing bone marrow stem cells</measure>
    <time_frame>1 year</time_frame>
    <description>based on cluster of differentiation 34 (CD34) and white blood cell (WBC) counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of compound muscle action potential in ulnar and peroneal nerve</measure>
    <time_frame>1 year</time_frame>
    <description>based on compound muscle action potential (CMAP) measured in nerve conduction study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>based on Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle power</measure>
    <time_frame>1 year</time_frame>
    <description>based on Muscle Manual Test (MMT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Granulocyte Colony Stimulating Factor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 0.01 ml/kg/day for 5 days subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <arm_group_label>Granulocyte Colony Stimulating Factor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 85

          -  definite or probable ALS according to revised El Escorial criteria

          -  maximum 2 years from initiation of symptoms to study entry

          -  mild to moderate disability according to revised ALS functional rating scale
             (ALSFRS-r)

        Exclusion Criteria:

          -  familial ALS

          -  pregnancy or lactation

          -  myeloproliferative or hematologic disorders

          -  active immunological disease

          -  liver or renal or heart disease

          -  HIV positive

          -  significant cognitive disorder

          -  hypersensitivity to GCSF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Iranian Neurology Research Center of Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>November 10, 2013</last_update_submitted>
  <last_update_submitted_qc>November 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Granulocyte Colony Stimulating Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

